Idorsia Pharmaceuticals

• NCT06816433

  Collaborator, Phase 2, Suspended, 200 people, 10 Feb 2025

• NCT05480488

  Phase 1, Completed, 18 people, 29 Jul 2022

• NCT05480475

  Phase 1, Completed, 24 people, 29 Jul 2022

• NCT03339752

  Phase 1, Completed, 20 people, 13 Nov 2017

• NCT03245229

  Phase 1, Completed, 20 people, 10 Aug 2017

• NCT01264692

  Phase 2, Completed, 196 people, 22 Dec 2010

• Insomnia as risk factor for brain, mental and general health consequences: an umbrella systematic review

  7 Sept 2026

Sources: api.crossref.org

• A scalable workflow using digital cognitive assessment and pTau217 for MCI detection

  Fees or honoraria, Grants or research support, 17 Sept 2026

• Primary results of the VICTORION-NOVEL (LDL-C management Program in atherosclerotic cardiovascular disease patients with elevated LDL-C) lipid optimization multicenter implementation trial

  Consulting or advice, Grants or research support, Board or leadership role, 16 Jul 2026

• Sleep and circadian rhythms in cardiovascular resilience: mechanisms, implications, and a Roadmap for research and interventions

  Consulting or advice, Fees or honoraria, 18 Sept 2025

Sources: pubmed.ncbi.nlm.nih.gov